Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study

BMC Ophthalmology

Research Article

Thomas F Goss¹  Xiao Xu²  Pamela A Weber³  Gergana Zlateva⁴  Barbara M Wirostko⁴ 

[1] Covance Market Access Services, Inc, 9801 Washingtonian Boulevard, 9th Floor Gaithersburg, 20878, Maryland, USA;Boston Health Care Associates, Boston, Massachusetts, USA;Covance Market Access Services, Inc, 9801 Washingtonian Boulevard, 9th Floor Gaithersburg, 20878, Maryland, USA;Johns Hopkins University, Baltimore, Maryland, USA;Island Retina, 1500 William Floyd Parkway, Suite 304, 11967, Shirley, New York, USA;Pfizer Inc, 235 East 42nd Street, 10017, New York, New York, USA;

关键词: Visual Acuity;    Ranibizumab;    Verteporfin;    Geographic Atrophy;    Pegaptanib;   

DOI  :  10.1186/1471-2415-10-2

 received in 2009-09-17, accepted in 2010-02-09,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundStudies have shown that early detection and treatment of neovascular age-related macular degeneration (NV-AMD) can delay vision loss and blindness. The objective of this study was to evaluate the efficacy/safety of intravitreal pegaptanib sodium monotherapy in treatment-naïve subjects with newly diagnosed NV-AMD and to gain insight into characteristics of lesions treated in community-based practices.MethodsFrom seven private US practices, charts were retrospectively reviewed on 73 subjects with previously untreated subfoveal choroidal NV-AMD treated with their first dose of pegaptanib monotherapy on/after 4/1/2005 through 6/5/2006, receiving ≥4 treatments at 6-week intervals over 21 weeks. Primary endpoint: mean visual acuity (VA) change from baseline to month 6.Results75% of lesions were occult, and 82% were subfoveal. From baseline to month 6, mean VA change was -0.68 lines; 58% and 16% gained ≥0 and ≥3 lines of VA, and 70% were responders (<3 lines lost). In 35 subjects with early disease, 80% were responders with a mean gain of 0.46 lines.ConclusionPegaptanib is effective in real-world patients with treatment-naïve NV-AMD in uncontrolled community-based retina practices.

【 授权许可】

Unknown   
© Weber et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.